policy
Regenerative medicine, including therapeutic use of stem cells
Regenerative medicine holds promise in treating a variety of diseases, yet questions remain. The AVMA supports the continued scientific development of…
policy
Guidelines for use of autogenous biologics
Autogenous biological products may provide veterinarians a unique opportunity for control of certain infectious diseases when USDA-licensed commercial…
policy
Development of emerging disease agent biologics
Development of emerging infectious disease biologics is essential for One Health. The AVMA supports the development of these products through…
JAVMA news
Vaccine holds promise for treating osteosarcoma in dogs
Veterinarians in the audience wanted to know when they could get their hands on the new treatment. Dr. Sue Ettinger, a veterinary oncologist, had…
JAVMA news
The risky business of global animal movement
Likely sources of another pandemic are being scrutinized like never before, including the global movement of animals via international trade and…
AVMA news
FDA approves anemia drug for cats with chronic kidney disease
Varenzin-CA1 from Elanco is the first drug for the control of nonregenerative anemia associated with chronic kidney disease in cats to receive…
JAVMA news
New listings in AVMA Animal Health Studies Database
Below are some of the new listings of veterinary clinical studies in the AVMA Animal Health Studies Database.
JAVMA news
AAHA releases new guidelines on canine vaccination
The American Animal Hospital Association announced Sept. 5 that it has released new guidelines on canine vaccination.
JAVMA news
The continuing conundrum of feline injection-site sarcomas
Veterinarians would much rather talk with cat owners about all the advantages of vaccination for cats rather than the extremely rare occurrence of…